﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Cision News</title><link>https://news.cision.com</link><description>Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.</description><pubDate>Wed, 10 Jun 2026 09:13:25 GMT</pubDate><image><title>Cision News</title><width>146</width><height>60</height><link>https://news.cision.com</link><url>https://news.cision.com/Content/img/news-logo.png</url></image><item><title>Genetic Immunity Clinical Trial Data Published in Plos One</title><link>http://news.cision.com/genetic-immunity/r/genetic-immunity-clinical-trial-data-published-in-plos-one,c9261342</link><guid isPermaLink="false">cision495341</guid><description><![CDATA[Genetic Immunity Clinical Trial Data Published in Plos OneDermaVir Immunization Boosted Long-lasting Memory T-cell Responses in Every Patient
McLean, VA and Budapest, Hungary, May 17, 2102 – Genetic Immunity Inc (http://www.geneticimmunity.com/)., a privately-held, biopharmaceutical company developing Langerhans cell-targeted immunotherapies, published its human proof-of-concept clinical trial, in PLoS ONE, a highly-regarded medical industry publication. The data demonstrated the induction of long-lasting memory T cell responses after a single immunization of DermaVir, the Company’s lead]]></description><pubDate>Thu, 17 May 2012 14:00:00 GMT</pubDate></item></channel></rss>